$1.86
2.62% yesterday
Nasdaq, Jun 13, 10:09 pm CET
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Nkarta Inc Stock price

$1.86
-0.08 4.12% 1M
-0.48 20.51% 6M
-0.63 25.30% YTD
-4.37 70.14% 1Y
-46.04 96.12% 5Y
-46.04 96.12% 10Y
-46.04 96.12% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.05 2.62%
ISIN
US65487U1088
Symbol
NKTX
Sector
Industry

Key metrics

Market capitalization $131.98m
Enterprise Value $-133.53m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.27
P/B ratio (TTM) P/B ratio 0.35
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-132.28m
Free Cash Flow (TTM) Free Cash Flow $-105.06m
Cash position $265.51m
EPS (TTM) EPS $-1.51
P/E forward negative
Short interest 13.13%
Show more

Is Nkarta Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Nkarta Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Nkarta Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Nkarta Inc forecast:

Buy
86%
Hold
14%

Financial data from Nkarta Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 36 36
21% 21%
-
- Research and Development Expense 96 96
0% 0%
-
-123 -123
0% 0%
-
- Depreciation and Amortization 9.19 9.19
25% 25%
-
EBIT (Operating Income) EBIT -132 -132
1% 1%
-
Net Profit -111 -111
5% 5%
-

In millions USD.

Don't miss a Thing! We will send you all news about Nkarta Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Nkarta Inc Stock News

Neutral
GlobeNewsWire
8 days ago
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He repl...
Neutral
GlobeNewsWire
about one month ago
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eli...
Neutral
GlobeNewsWire
2 months ago
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
More Nkarta Inc News

Company Profile

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Paul Hastings
Employees 157
Founded 2005
Website www.nkartatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today